Barclays initiated coverage of GoodRx with an Overweight rating and $8 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX:
- GoodRx (NASDAQ:GDRX) Turns Bad after Stock Downgrade
- Jefferies specialty pharmaceuticals analyst has analyst/industry conference call
- GoodRx management to meet virtually with KeyBanc
- CVS CostVantage to lower value proposition offered by GoodRx, says Wells Fargo
- Hims & Hers weight loss solution ‘will be welcomed,’ says Citi